Rajesh Narendran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rajesh Narendran has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- William Gordon Frankle
Department of Psychiatry, NYU Langone Medical Center, New York, New York
15 shared publications Michael L. Himes
Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
14 shared publicationsN. Scott Mason
Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
12 shared publicationsBrian J. Lopresti
Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
7 shared publicationsBrian Lopresti
Department of Radiology, University of Pittsburgh, Pittsburgh, USA
7 shared publicationsChester A. Mathis
From the Departments of Radiology and Psychiatry, University of Pittsburgh; and the Department of Psychiatry, Columbia University Medical Center, New York
7 shared publications
Latest Publications
- Open Access
- 17 February 2026
- Published byĀ American Society for Clinical InvestigationĀ inĀ Journal of Clinical Investigation
- Vol.Ā 136 Ā (7)
Synaptic loss in alcohol use disorder: clinical and mechanistic insights from a PET imaging study
Alcohol use disorder (AUD) is linked with changes in brain structure and function, with robust evidence for neurodegenerative changes, including synaptic loss in preclinical models. Developing therapeutic strategies to target synaptic loss will require human studies that clarify their clinical relevance of these changes. In the current issue, Zakiniaeiz et al. demonstrate that AUD and alcohol consumption are associated with lower synaptic vesicle glycoprotein 2a (SV2A) expression, indexed by regional [ 11 C]UCB-J PET. This is, to our knowledge, the first in vivo evidence of relationships between synaptic density and alcohol use, and, as such, it represents an important step toward understanding how AUD influences brain structure and function. Here, we describe two longstanding clinical issues in the AUD population ā relapse and dementia risk ā and how the results of the present study may guide future investigations of these issues.
- 17 February 2026
- Published byĀ American Society for Clinical InvestigationĀ inĀ Journal of Clinical Investigation
- Vol.Ā 136 Ā (7)
Open AccessSynaptic loss in alcohol use disorder: clinical and mechanistic insights from a PET imaging study
Alcohol use disorder (AUD) is linked with changes in brain structure and function, with robust evidence for neurodegenerative changes, including synaptic loss in preclinical models. Developing therapeutic strategies to target synaptic loss will require human studies that clarify their clinical relevance of these changes. In the current issue, Zakiniaeiz et al. demonstrate that AUD and alcohol consumption are associated with lower synaptic vesicle glycoprotein 2a (SV2A) expression, indexed by regional [ 11 C]UCB-J PET. This is, to our knowledge, the first in vivo evidence of relationships between synaptic density and alcohol use, and, as such, it represents an important step toward understanding how AUD influences brain structure and function. Here, we describe two longstanding clinical issues in the AUD population ā relapse and dementia risk ā and how the results of the present study may guide future investigations of these issues.
- 4 January 2023
- Published byĀ ElsevierĀ inĀ Biological Psychiatry
- Vol.Ā 94 Ā (5) , 416-423
Imaging Nociceptin Opioid Peptide Receptors in Alcohol Use Disorder With [11C]NOP-1A and Positron Emission Tomography: Findings From a Second Cohort
- 4 January 2023
- Published byĀ ElsevierĀ inĀ Biological Psychiatry
- Vol.Ā 94 Ā (5) , 416-423
Imaging Nociceptin Opioid Peptide Receptors in Alcohol Use Disorder With [11C]NOP-1A and Positron Emission Tomography: Findings From a Second Cohort
- 1 October 2022
- Published byĀ ElsevierĀ inĀ Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol.Ā 7 Ā (10) , 998-1006
Imaging the Influence of Red Blood Cell Docosahexaenoic Acid Status on the Expression of the 18 kDa Translocator Protein in the Brain: A [11C]PBR28 Positron Emission Tomography Study in Young Healthy Men
- 1 October 2022
- Published byĀ ElsevierĀ inĀ Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol.Ā 7 Ā (10) , 998-1006
Imaging the Influence of Red Blood Cell Docosahexaenoic Acid Status on the Expression of the 18 kDa Translocator Protein in the Brain: A [11C]PBR28 Positron Emission Tomography Study in Young Healthy Men
- 29 July 2022
- Published byĀ WileyĀ inĀ Journal of Neurochemistry
- Vol.Ā 164 Ā (3) , 401-443
Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders
Early applications of positron emission tomography (PET) in psychiatry sought to identify derangements of cerebral blood flow and metabolism. The need for more specific neurochemical imaging probes was soon evident, and these probes initially targeted the sites of action of neuroleptic (dopamine D-2 receptors) and psychoactive (serotonin receptors) drugs. For nearly 30years, the centrality of monoamine dysfunction in psychiatric disorders drove the development of an armamentarium of monoaminergic PET radiopharmaceuticals and imaging methodologies. However, continued investments in monoamine-enhancing drug development realized only modest gains in efficacy and tolerability. As patent protection for many widely prescribed and profitable psychiatric drugs lapsed, drug development pipelines shifted away from monoamines in search of novel targets with the promises of improved efficacy, or abandoned altogether. Over this period, PET radiopharmaceutical development activities closely parallelled drug development priorities, resulting in the development of new PET imaging agents for non-monoamine targets. In part two of this review, we survey clinical research studies using the novel targets and radiotracers described in part one across major psychiatric application areas such as substance use disorders, anxiety disorders, eating disorders, personality disorders, mood disorders, and schizophrenia. Important limitations of the studies described are discussed, as well as key methodologic issues, challenges to the field, and the status of clinical trials seeking to exploit these targets for novel therapeutics.
- 29 July 2022
- Published byĀ WileyĀ inĀ Journal of Neurochemistry
- Vol.Ā 164 Ā (3) , 401-443
Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders
Early applications of positron emission tomography (PET) in psychiatry sought to identify derangements of cerebral blood flow and metabolism. The need for more specific neurochemical imaging probes was soon evident, and these probes initially targeted the sites of action of neuroleptic (dopamine D-2 receptors) and psychoactive (serotonin receptors) drugs. For nearly 30years, the centrality of monoamine dysfunction in psychiatric disorders drove the development of an armamentarium of monoaminergic PET radiopharmaceuticals and imaging methodologies. However, continued investments in monoamine-enhancing drug development realized only modest gains in efficacy and tolerability. As patent protection for many widely prescribed and profitable psychiatric drugs lapsed, drug development pipelines shifted away from monoamines in search of novel targets with the promises of improved efficacy, or abandoned altogether. Over this period, PET radiopharmaceutical development activities closely parallelled drug development priorities, resulting in the development of new PET imaging agents for non-monoamine targets. In part two of this review, we survey clinical research studies using the novel targets and radiotracers described in part one across major psychiatric application areas such as substance use disorders, anxiety disorders, eating disorders, personality disorders, mood disorders, and schizophrenia. Important limitations of the studies described are discussed, as well as key methodologic issues, challenges to the field, and the status of clinical trials seeking to exploit these targets for novel therapeutics.
- 10 May 2022
- Published byĀ WileyĀ inĀ Journal of Neurochemistry
- Vol.Ā 164 Ā (3) , 364-400
Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders
With the emergence of positron emission tomography (PET) in the late 1970s, psychiatry had access to a tool capable of nonāinvasive assessment of human brain function. Early applications in psychiatry focused on identifying characteristic brain blood flow and metabolic derangements using radiotracers such as [15O]H2O and [18F]FDG. Despite the success of these techniques, it became apparent that more specific probes were needed to understand the neurochemical bases of psychiatric disorders. The first neurochemical PET imaging probes targeted sites of action of neuroleptic (dopamine D2 receptors) and psychoactive (serotonin receptors) drugs. Based on the centrality of monoamine dysfunction in psychiatric disorders and the measured success of monoamineāenhancing drugs in treating them, the next 30 years witnessed the development of an armamentarium of PET radiopharmaceuticals and imaging methodologies for studying monoamines. Continued development of monoamineāenhancing drugs over this time however was less successful, realizing only modest gains in efficacy and tolerability. As patent protection for many widely prescribed and profitable psychiatric drugs lapsed, drug development pipelines shifted away from monoamines in search of novel targets with the promises of improved efficacy, or abandoned altogether. Over this period, PET radiopharmaceutical development activities closely paralleled drug development priorities resulting in the development of new PET imaging agents for nonāmonoamine targets. Part one of this review will briefly survey novel PET imaging targets with relevance to the field of psychiatry, which include the metabotropic glutamate receptor type 5 (mGluR5), purinergic P2X7 receptor, type 1 cannabinoid receptor (CB1), phosphodiesterase 10A (PDE10A), and describe radiotracers developed for these and other targets that have matured to human subject investigations. Current limitations of the targets and techniques will also be discussed. image
- 10 May 2022
- Published byĀ WileyĀ inĀ Journal of Neurochemistry
- Vol.Ā 164 Ā (3) , 364-400
Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders
With the emergence of positron emission tomography (PET) in the late 1970s, psychiatry had access to a tool capable of nonāinvasive assessment of human brain function. Early applications in psychiatry focused on identifying characteristic brain blood flow and metabolic derangements using radiotracers such as [15O]H2O and [18F]FDG. Despite the success of these techniques, it became apparent that more specific probes were needed to understand the neurochemical bases of psychiatric disorders. The first neurochemical PET imaging probes targeted sites of action of neuroleptic (dopamine D2 receptors) and psychoactive (serotonin receptors) drugs. Based on the centrality of monoamine dysfunction in psychiatric disorders and the measured success of monoamineāenhancing drugs in treating them, the next 30 years witnessed the development of an armamentarium of PET radiopharmaceuticals and imaging methodologies for studying monoamines. Continued development of monoamineāenhancing drugs over this time however was less successful, realizing only modest gains in efficacy and tolerability. As patent protection for many widely prescribed and profitable psychiatric drugs lapsed, drug development pipelines shifted away from monoamines in search of novel targets with the promises of improved efficacy, or abandoned altogether. Over this period, PET radiopharmaceutical development activities closely paralleled drug development priorities resulting in the development of new PET imaging agents for nonāmonoamine targets. Part one of this review will briefly survey novel PET imaging targets with relevance to the field of psychiatry, which include the metabotropic glutamate receptor type 5 (mGluR5), purinergic P2X7 receptor, type 1 cannabinoid receptor (CB1), phosphodiesterase 10A (PDE10A), and describe radiotracers developed for these and other targets that have matured to human subject investigations. Current limitations of the targets and techniques will also be discussed. image
- Open Access
- 1 May 2021
- Published byĀ Springer NatureĀ inĀ Translational Psychiatry
- Vol.Ā 11 Ā (1) , 1-11
Imaging beta-amyloid (Aβ) burden in the brains of middle-aged individuals with alcohol-use disorders: a [11C]PIB PET study
No in vivo human studies have examined the prevalence of Alzheimerās disease (AD) neuropathology in individuals with alcohol-use disorder (AUD), although recent research suggests that a relationship between the two exists. Therefore, this study used Pittsburgh Compound-B ([11C]PiB) PET imaging to test the hypothesis that AUD is associated with greater brain amyloid (Aβ) burden in middle-aged adults compared to healthy controls. Twenty healthy participants (14M and 6F) and 19 individuals with AUD (15M and 4F), all aged 40ā65 years, underwent clinical assessment, MRI, neurocognitive testing, and positron emission tomography (PET) imaging. Global [11C]PiB standard uptake value ratios (SUVRs), cortical thickness, gray matter volumes (GMVs), and neurocognitive function in subjects with AUD were compared to healthy controls. These measures were selected because they are considered markers of risk for future AD and other types of neurocognitive dysfunction. The results of this study showed no significant differences in % global Aβ positivity or subthreshold Aβ loads between AUD and controls. However, relative to controls, we observed a significant 6.1% lower cortical thickness in both AD-signature regions and in regions not typically associated with AD, lower GMV in the hippocampus, and lower performance on tests of attention as well as immediate and delayed memory in individuals with AUD. This suggest that Aβ accumulation is not greater in middle-aged individuals with AUD. However, other markers of neurodegeneration, such as impaired memory, cortical thinning, and reduced hippocampal GMV, are present. Further studies are needed to elucidate the patterns and temporal staging of AUD-related pathophysiology and cognitive impairment. Imaging β-amyloid in middle age alcoholics as a mechanism that increases their risk for Alzheimerās disease; Registration Number: NCT03746366.
- 1 May 2021
- Published byĀ Springer NatureĀ inĀ Translational Psychiatry
- Vol.Ā 11 Ā (1) , 1-11
Open AccessImaging beta-amyloid (Aβ) burden in the brains of middle-aged individuals with alcohol-use disorders: a [11C]PIB PET study
No in vivo human studies have examined the prevalence of Alzheimerās disease (AD) neuropathology in individuals with alcohol-use disorder (AUD), although recent research suggests that a relationship between the two exists. Therefore, this study used Pittsburgh Compound-B ([11C]PiB) PET imaging to test the hypothesis that AUD is associated with greater brain amyloid (Aβ) burden in middle-aged adults compared to healthy controls. Twenty healthy participants (14M and 6F) and 19 individuals with AUD (15M and 4F), all aged 40ā65 years, underwent clinical assessment, MRI, neurocognitive testing, and positron emission tomography (PET) imaging. Global [11C]PiB standard uptake value ratios (SUVRs), cortical thickness, gray matter volumes (GMVs), and neurocognitive function in subjects with AUD were compared to healthy controls. These measures were selected because they are considered markers of risk for future AD and other types of neurocognitive dysfunction. The results of this study showed no significant differences in % global Aβ positivity or subthreshold Aβ loads between AUD and controls. However, relative to controls, we observed a significant 6.1% lower cortical thickness in both AD-signature regions and in regions not typically associated with AD, lower GMV in the hippocampus, and lower performance on tests of attention as well as immediate and delayed memory in individuals with AUD. This suggest that Aβ accumulation is not greater in middle-aged individuals with AUD. However, other markers of neurodegeneration, such as impaired memory, cortical thinning, and reduced hippocampal GMV, are present. Further studies are needed to elucidate the patterns and temporal staging of AUD-related pathophysiology and cognitive impairment. Imaging β-amyloid in middle age alcoholics as a mechanism that increases their risk for Alzheimerās disease; Registration Number: NCT03746366.
- 12 April 2020
- Published byĀ ElsevierĀ inĀ Biological Psychiatry
- Vol.Ā 88 Ā (10) , 788-796
Imaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457āAmphetamine Positron Emission Tomography Study
- 12 April 2020
- Published byĀ ElsevierĀ inĀ Biological Psychiatry
- Vol.Ā 88 Ā (10) , 788-796
Imaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457āAmphetamine Positron Emission Tomography Study
- 1 June 2019
- Published byĀ American Psychiatric Association PublishingĀ inĀ American Journal of Psychiatry
- Vol.Ā 176 Ā (6) , 468-476
Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [11C]NOP-1A
Objective:Nociceptin/orphanin FQ (N/OFQ) is an antistress neuropeptide transmitter in the brain that counteracts corticotropin-releasing factor (CRF)-mediated stress and anxiety symptoms during dru...
- 1 June 2019
- Published byĀ American Psychiatric Association PublishingĀ inĀ American Journal of Psychiatry
- Vol.Ā 176 Ā (6) , 468-476
Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [11C]NOP-1A
Objective:Nociceptin/orphanin FQ (N/OFQ) is an antistress neuropeptide transmitter in the brain that counteracts corticotropin-releasing factor (CRF)-mediated stress and anxiety symptoms during dru...
- 1 June 2019
- Published byĀ ElsevierĀ inĀ Biological Psychiatry
- Vol.Ā 85 Ā (12) , 1056-1064
Decreased Nociceptin Receptors Are Related to Resilience and Recovery in College Women Who Have Experienced Sexual Violence: Therapeutic Implications for Posttraumatic Stress Disorder
- 1 June 2019
- Published byĀ ElsevierĀ inĀ Biological Psychiatry
- Vol.Ā 85 Ā (12) , 1056-1064
Decreased Nociceptin Receptors Are Related to Resilience and Recovery in College Women Who Have Experienced Sexual Violence: Therapeutic Implications for Posttraumatic Stress Disorder